Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of baohuoside I in preparation of drugs for treating asthma

A technology of baohuoside and its application is applied in the field of preparing drugs for treating allergic asthma, and can solve the problems that have not yet been seen, and the protein expression can be reduced.

Inactive Publication Date: 2017-03-22
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have reported that baohuoside Ⅰ can inhibit the proliferation of activated T cells, inhibit the proliferation of Eca-109 cells, reduce the expression of β-catenin, Cyclin D1, Survivin mRNA and protein, and inhibit the proliferation of breast cancer cell MCF-7; Effects of Baohuoside Ⅰ on Asthma and T-cell Induced Immune Inflammation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of baohuoside I in preparation of drugs for treating asthma
  • Application of baohuoside I in preparation of drugs for treating asthma
  • Application of baohuoside I in preparation of drugs for treating asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Effect of Baohuoside I on AHR of Airway Hyperresponsiveness in Mouse Asthma Model

[0024] The baohuoside I monomer of the formula (I) is obtained by separating and preparing the baohuoside I monomer of the formula (I) through the commercial channel or using the crude extract of Epimedium herba as raw material, and its molecular formula is: C 27 h 30 o 10 , Molecular weight: 514.5211.

[0025] 60 female BALB / c mice aged 7 weeks in healthy and clean grade, with a body weight of 16-18 g (provided by Shanghai Xipuerbikai Experimental Animal Co., Ltd.), were randomly divided into 6 groups, 10 in each group, namely the normal control group ( NC), asthma model group (AS), dexamethasone intervention group (DEX), baohuoside Ⅰ low, medium, and high dose intervention groups (BL, BM, BH); mice were given a one-time intraperitoneal injection from day 0 0.2ml of physiological saline suspension of 20ug ovalbumin and 2mg aluminum hydroxide was used to make the mice in a s...

Embodiment 2

[0029] Example 2 Effect of baohuoside I on airway inflammation in ovalbumin-induced mouse asthma model

[0030] The right lung tissue of the experimental mice was taken, after conventional treatment, soaked and fixed in 4% neutral formaldehyde, embedded in paraffin, stained with HE, and observed with a light microscope for inflammatory changes; the results showed that the airways and surrounding lung tissues of the mice in the asthma model group were visible The infiltration of inflammatory cells such as neutrophils, lymphocytes, macrophages and eosinophils; the intervention of baohuoside I can significantly reduce the inflammatory changes such as inflammatory cell infiltration and alveolar congestion in the airway wall of mice.

Embodiment 3

[0031] Example 3 Effect of Baohuoside I on Inflammatory Cells in Ovalbumin-Induced Mouse Asthma Model BALF

[0032] After the experimental mice completed the lung function measurement, insert a tracheal lavage needle into the left bronchus, open the chest and ligate the right main bronchus and right lung, and use 0.3ml PBS to lavage the left lung twice; the recovered BALF was 800g at 4°C After ×10min centrifugation, the cell pellet was resuspended with 100ul PBS solution, and the white blood cell differential count was carried out; the results showed that, compared with the normal group, the total white blood cell count (WBC), neutrophil (NEU), lymphocyte ( LYM), monocytes (MON), eosinophils (EOS), and basophils (BAS) were significantly increased; Baohuoside Ⅰ low-dose group could significantly reduce WBC, NEU, MON and EOS cells in BALF Quantity (p<0.05).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of pharmacy, relates to a novel medical application of baohuoside I, and specifically relates to an application of baohuoside I in the preparation of drugs for treating asthma, especially drugs for treating allergic asthma. The results of in-vivo animal experiments and in-vitro CD4+T cell culture experiments show that baohuoside I can prominently reduce the bronchial hyper-responsiveness of asthmatic mice, inhibit the airway inflammation, reduce the number of inflammation cells in a bronchoalveolar lavage fluid, inhibit the secretion of chemotactic factors, promote the differentiation of Th1 cells and Treg cells, inhibit IL-17A, and promote the secretion of IFN-gamma and IL-10. The provided baohuoside I can be used as a single component for the preparation of drugs for treating asthma, and is further used to treat asthma, especially allergic asthma.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to the new medicinal use of baohuoside I, in particular to the use of baohuoside I in preparing medicines for treating asthma, especially the use in preparing medicines for treating allergic asthma. Background technique [0002] The prior art discloses that asthma is a chronic airway inflammatory disease involving various cells and cell components. This chronic inflammation often leads to increased airway responsiveness to various stimuli, resulting in reversible airflow limitation, causing Recurrent wheezing, shortness of breath, chest tightness, coughing and other symptoms. The pathogenesis of asthma has not yet been fully clarified. Studies have shown that genetic factors and environmental factors often lead to persistent airway inflammation, reversible airway obstruction, airway hyperresponsiveness (AHR) and airway weight loss in patients with asthma. Among them, allergen-induced T cell a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P11/06
Inventor 董竞成魏颖杜鑫刘家齐孙婧张红英吕玉宝
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com